
Disclosure of Value Transfers

Methodological Note

Country	Serbia
Entity Name	Fresenius-Kabi doo Beograd
Legal Basis for Disclosure	Medicines for Europe Code of Conduct 2020, published February 2021
Reporting Period	2022
Currency of disclosed values	All values are disclosed in <input checked="" type="checkbox"/> EUR <input type="checkbox"/> [local currency, if required]
Scope of disclosure	The disclosure covers all interactions with HCPs related to prescription-only medicines for human use
Value identification and Recognition	All values disclosed are based on value transfers actually made the respective category that such value transfer has been made to a specific recipient as booked in the respective reporting period.
Multi-Year Contracts	Value transfers under multiyear contracts are part of the disclosed data to the extent that actual value transfers have been made in the respective reporting period.
Data disclosed for	All values are disclosed for <input type="checkbox"/> Recipients which have been engaged by entity <input checked="" type="checkbox"/> Recipients who have their residence in the country (e.g., EFPIA and Medicines for Europe)
VAT and other taxes	All amounts are disclosed include VAT or similar service taxes, where such apply on the transaction
Disclosure location:	www.fresenius-kabi.com/documents/Disclosure-2022-Serbia.pdf

Disclosure of Value Transfers

Other Remarks	For value categories related to HCPs, aggregate values have been disclosed where the consent of a multiple number of HCP could not be obtained. Fees paid in connection with research & development activities or market research have not been disclosed.
----------------------	---